Developing innovative cancer treatments tackling GPCR mediated-immunosuppression
Discovery | Candidate | Preclinical | Clinical | Partner | |
---|---|---|---|---|---|
A2aR/A2bR antagonist + |
Clinical
![]() |
||||
EP4 receptor antagonist ( DT-9081 ) + | Preclinical | ||||
Anti-CCR8 antibody + | Discovery | ||||
Undisclosed GPCR targets + | Discovery |
We build a high value pipeline focused on GPCRs to rearm immune system against tumors.